REGN10597 not checked
Regeneron · PD-1-IL2Ra-IL2 immunotherapy
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Non Small Cell Lung Cancer, NSCLC, Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Main trialPhase 2
- “This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study…”In the company’s words, NCT06787612 on ClinicalTrials.gov
- Other names
- PD-1-IL2Ra-IL2 immunotherapy
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up3
- 30 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- 4 Dec 2029Phase 2 trial completes · ClinicalTrials.gov
- 3 Feb 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jun 2028 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | |
| Phase 2Active, not recruiting | 4 Dec 2029 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | |
| Phase 1/2Recruiting | 3 Feb 2030 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026